We are live on ! Find out more
BAMS

Bellevue Asset Management (Switzerland) Portfolio holdings

AUM $656M
1-Year Est. Return 11.45%
This Fund
S&P 500
This Quarter Est. Return
+4.85%
1 Year Est. Return
+11.45%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$721M
AUM Growth
+$3.8M
Cap. Flow
-$22.4M
Cap. Flow %
-3.1%
Top 10 Hldgs %
29.13%
Holding
154
New
13
Increased
38
Reduced
45
Closed
15

Top Buys

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$6.22M
2
COR icon
Cencora
COR
+$5.63M
3
ILMN icon
Illumina
ILMN
+$5.46M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$4.98M
5
PRGO icon
Perrigo
PRGO
+$4.77M

Top Sells

Rank Stock Value
1
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$18.9M
2
BAX icon
Baxter International
BAX
+$9.56M
3
CNC icon
Centene
CNC
+$8.47M
4
LCI
Lannett Company, Inc.
LCI
+$6.61M
5
MOH icon
Molina Healthcare
MOH
+$6.39M

Sector Composition

Rank Sector Weight
1 Healthcare 90.06%
2 Financials 0.8%
3 Industrials 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JUNO
76
DELISTED
Juno Therapeutics, Inc.
JUNO
$2.56M 0.36%
+48,000
New +$2.55M
NKTR icon
77
Nektar Therapeutics
NKTR
$2.54B
$2.5M 0.35%
13,333
+5,600
+72% +$964K
THOR
78
DELISTED
THORATEC CORPORATION
THOR
$2.45M 0.34%
55,000
– –
GMED icon
79
Globus Medical
GMED
$11.5B
$2.25M 0.31%
87,700
-2,300
-3% -$58.2K
ESPR
80
DELISTED
Esperion Therapeutics
ESPR
$2.21M 0.31%
+27,000
New +$2.64M
HCSG icon
81
Healthcare Services Group
HCSG
$1.52B
$2.15M 0.3%
+65,000
New +$2.05M
NUVA
82
DELISTED
NuVasive, Inc.
NUVA
$2.13M 0.3%
45,000
– –
HALO icon
83
Halozyme
HALO
$12.2B
$2.07M 0.29%
91,616
– –
DVA icon
84
DaVita
DVA
$11.7B
$2.07M 0.29%
26,000
– –
SRCL
85
DELISTED
Stericycle Inc
SRCL
$2.01M 0.28%
15,000
-6,000
-29% -$822K
SGEN
86
DELISTED
Seagen Inc. Common Stock
SGEN
$1.94M 0.27%
40,000
– –
CLDX icon
87
Celldex Therapeutics
CLDX
$3.35B
$1.87M 0.26%
4,933
-2,000
-29% -$794K
ABBV icon
88
AbbVie
ABBV
$434B
$1.81M 0.25%
27,000
-3,000
-10% -$196K
ICPT
89
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.81M 0.25%
7,500
+1,000
+15% +$266K
INFI
90
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.8M 0.25%
164,000
– –
MNKD icon
91
MannKind Corp
MNKD
$1.27B
$1.71M 0.24%
60,000
– –
WCG
92
DELISTED
Wellcare Health Plans, Inc.
WCG
$1.7M 0.24%
20,000
+12,000
+150% +$1.01M
TMO icon
93
Thermo Fisher Scientific
TMO
$220B
$1.69M 0.23%
13,000
– –
LLY icon
94
Eli Lilly
LLY
$1.08T
$1.67M 0.23%
+20,000
New +$1.52M
ANGO icon
95
AngioDynamics
ANGO
$649M
$1.64M 0.23%
100,000
– –
INO icon
96
Inovio Pharmaceuticals
INO
$72.6M
$1.63M 0.23%
16,667
-8,333
-33% -$890K
PODD icon
97
Insulet
PODD
$9.91B
$1.63M 0.23%
52,500
– –
DHR icon
98
Danaher
DHR
$145B
$1.63M 0.23%
28,269
– –
UTHR icon
99
United Therapeutics
UTHR
$22.5B
$1.62M 0.22%
9,300
– –
HTWR
100
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$1.6M 0.22%
22,000
– –
2 3
4
5 6

Similar funds

VFAM
Valley Forge Asset Management King Of Prussia, Pennsylvania $645M AUM 5.8% 1-Year Est. Return
MSU
Maple Securities USA Jersey City, New Jersey $672M AUM 1.03% 1-Year Est. Return
PSI
Pinnacle Summer Investments Fairfax, Virginia $678M AUM 9.5% 1-Year Est. Return
SFP
Santa Fe Partners Santa Fe, New Mexico $608M AUM 8.76% 1-Year Est. Return
MCM
Mazama Capital Management Portland, Oregon $544M AUM 9.52% 1-Year Est. Return
NMIS
Northwestern Mutual Investment Services Milwaukee, Wisconsin $525M AUM 2.45% 1-Year Est. Return
SM
Stratton Management King Of Prussia, Pennsylvania $824M AUM 1.57% 1-Year Est. Return
ZAM
Zenit Asset Management Stockholm, Sweden $450M AUM 8.32% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s Q2 2015 Portfolio in Review

As of Q2 2015, Bellevue Asset Management (Switzerland) held 154 positions worth $721M, up 0.53% from $717M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Bellevue Asset Management (Switzerland) withdrew a net $22.4M in Q2 2015, closing 15 positions and reducing 45 holdings. Its most notable exit was CATAMARAN CORP COM STK (CDA), an estimated $18.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 85% a quarter earlier, followed by Financials and Industrials.

Against the trend, Bellevue Asset Management (Switzerland) opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $5.21M.

  • Bellevue Asset Management (Switzerland)'s largest Q2 2015 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 150,000 shares worth $5.21M.
  • Bellevue Asset Management (Switzerland) added most to Endo International plc in Q2 2015, an estimated $6.22M increase.
  • Bellevue Asset Management (Switzerland)'s biggest Q2 2015 reduction was Centene, cutting an estimated $8.47M.
  • Bellevue Asset Management (Switzerland) fully exited CATAMARAN CORP COM STK (CDA) in Q2 2015, selling an estimated $18.9M.
  • Bellevue Asset Management (Switzerland)'s ten largest holdings make up 29% of its $721M portfolio in Q2 2015.
  • Bellevue Asset Management (Switzerland) opened 13 new positions and closed 15 in Q2 2015.
  • Bellevue Asset Management (Switzerland)'s portfolio value rose 0.53% quarter-over-quarter to $721M.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q2 2015, filed 12 Aug 2015.